Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Colchicine in Pulmonary Artery Hypertension Patients

NCT07907757 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07907757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Colchicine in Pulmonary Artery Hypertension Patients
Lead sponsor
Ain Shams University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2027
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension

Arms

As registered; 2 arms.

  • No intervention: Control group No intervention

    No intervention: Control group: Thirty patients shall receive standard of care treatment for 12 weeks.

    Standard of care treatment received by both groups would include pulmonary vasodilator therapy with Phosphodiesterase 5 inhibitors (PDE5), Endothelin receptor antagonists (ERA), and Prostacyclin analogues (PA), either alone or in combination, without any consideration by the treating medical team for escalation of treatment.

  • Experimental: Colchicine ExperimentalColchicine 0.5 MG Oral Tablet

    Experimental: Colchicine group: Thirty patients shall receive standard of care treatment in addition to 0.5 mg colchicine tablets per oral once daily for 12 weeks (Colchicine®, Tablets with a concentration of 500 micrograms, manufactured by Adwick-Al Nasr Pharmaceutical Chemicals Company, Abu Zaabal, Egypt).

Primary endpoints

Registered primary outcome measures; 1 primary.

  • WHO-FC 12 weeks

    One of the strongest predictors of survival at diagnosis and follow-up and worsening WHO-FC is one of the most alarming indicators of disease progression, which should trigger further investigation to identify the cause(s) of clinical deterioration

Lead sponsor's other trials

Ain Shams University, most recent start first.

Similar trials

Same condition (Hypertension, Pulmonary) and phase, most recent start first.